二甲双胍纠正糖尿病中异常昼夜节律与Kir4.1通道
本研究在db/db2型糖尿病小鼠模型及大鼠视网膜Müller细胞系(rMC-1)中,探讨口服二甲双胍对昼夜节律紊乱和Kir4.1通道功能障碍的纠正作用。结果显示二甲双胍改善小鼠跑轮活动节律、恢复Müller细胞Kir4.1水平并上调Opn4和Aanat等时钟调控基因;在rMC-1细胞中,二甲双胍与AICAR激活AMPK均增加Kir4.1和Bmal-1蛋白表达,而沉默Prkaa1则降低二者表达。结论提示二甲双胍可能成为预防人糖尿病视网膜病变中Müller细胞功能障碍的候选药物。
要点
- 二甲双胍改善db/db小鼠跑轮活动节律并恢复Müller细胞Kir4.1水平。
- 二甲双胍上调视网膜Opn4和Aanat等时钟调控基因表达。
- AMPK激活增加rMC-1细胞Kir4.1与Bmal-1蛋白,沉默Prkaa1则降低二者。
核心结论
- 二甲双胍可纠正db/db2型糖尿病小鼠模型的异常昼夜节律和Kir4.1通道功能障碍。
- 二甲双胍可能成为预防人糖尿病视网膜病变中Müller细胞功能障碍的重要药物。
研究设计与样本
- 研究对db/db小鼠口服给予二甲双胍,并在研究终点测定跑轮活动、视网膜Kir4.1水平与AMPK磷酸化。
- 平行使用大鼠视网膜Müller细胞系rMC-1,以二甲双胍和AICAR处理评估AMPK激活对Kir4.1通道的影响。
主要发现
- 二甲双胍治疗后db/db小鼠跑轮活动改善。
- 二甲双胍治疗后Müller细胞Kir4.1水平得到纠正。
- 二甲双胍上调黑视蛋白(Opn4)和芳烷基胺N-乙酰转移酶(Aanat)等时钟调控基因。
- rMC-1细胞中AICAR和二甲双胍激活AMPK导致Kir4.1与核心时钟成分Bmal-1蛋白表达增加。
- 沉默Prkaa1(AMPKα1基因)导致Kir4.1与Bmal-1蛋白表达降低。
临床怎么用
- 在2型糖尿病相关视网膜病变中,二甲双胍可能通过AMPK依赖途径改善Müller细胞Kir4.1通道与昼夜节律功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diabetic retinopathy (DR) is a leading cause of visual impairment. Müller cells in DR are dysfunctional due to downregulation of the inwardly rectifying potassium channel Kir4.1. Metformin, a commonly used oral antidiabetic drug, is known to elicit its action through 5' adenosine monophosphate-activated protein kinase (AMPK), a cellular metabolic regulator; however, its effect on Kir4.1 channels is unknown. For this study, we hypothesized that metformin treatment would correct circadian rhythm disruption and Kir4.1 channel dysfunction in db/db mice. METHODS: Metformin was given orally to db/db mice. Wheel-running activity, retinal levels of Kir4.1, and AMPK phosphorylation were determined at study termination. In parallel, rat retinal Müller cell line (rMC-1) cells were treated using metformin and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to assess the effect of AMPK activation on the Kir4.1 channel. RESULTS: The wheel-running activity of the db/db mice was improved following the metformin treatment. The Kir4.1 level in Müller cells was corrected after metformin treatment. Metformin treatment led to an upregulation of clock regulatory genes such as melanopsin (Opn4) and aralkylamine N-acetyltransferase (Aanat). In rMC-1 cells, AMPK activation via AICAR and metformin resulted in increased Kir4.1 and intermediate core clock component Bmal-1 protein expression. The silencing of Prkaa1 (gene for AMPKα1) led to decreased Kir4.1 and Bmal-1 protein expression. CONCLUSIONS: Our findings demonstrate that metformin corrects abnormal circadian rhythm and Kir4.1 channels in db/db mouse a model of type 2 diabetes. Metformin could represent a critical pharmacological agent for preventing Müller cell dysfunction observed in human DR.
引用
- Alex A, Luo Q, Mathew D, et al. Metformin Corrects Abnormal Circadian Rhythm and Kir4.1 Channels in Diabetes. Invest Ophthalmol Vis Sci. 2020. PMID: 32572457. doi:10.1167/iovs.61.6.46
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。